
-
Trevi Therapeutics NASDAQ:TRVI Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. Trevi is conducting a Phase 2b/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and a Phase 2 trial for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Trevi is also developing Haduvio for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease and is in the planning stages of a Phase 2 study in this indication. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
Location: | Website: www.trevitherapeutics.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
518.9M
Cash
107.6M
Avg Qtr Burn
-9.564M
Short % of Float
8.02%
Insider Ownership
0.90%
Institutional Own.
86.48%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Haduvio (oral nalbuphine ER) Details Idiopathic pulmonary fibrosis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2b Data readout | |
Haduvio (oral nalbuphine ER) Copy Details Refractory Chronic Cough | Phase 2a Update |